drugset / Trial / NCT04322344

Escin in Patients With Covid-19 Infection

NCT04322344

Non-randomizedParallel-groupDouble-blindSupportive care

Summary

In December 2019,a new type of pneumonia caused by the coronavirus (COVID-2019) broke out in Wuhan ,China, and spreads quickly to other Chinese cities and 28 countries. More than 70000 people were infected and over 2000 people died all over the world. There is no specific drug treatment for this disease. Considering that lung damage is related to both viral infection and burst of cytokines, our idea is to evaluate the efficacy and safety of escin as add-on treatment to conventional antiviral drugs in COVID-19 infected patients.

Timeline

Start
2020-03-23
Primary completion
2020-06-30
Completion
2020-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Escin Unknown 20 mg Oral
Subject Escin Unknown 40 mg Oral